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ABSTRACT

Institution: Mississippi State University
Major Field: Veterinary Medical Research
Major Professor: John M. Thomason
Title of Study: Effects of aspirin dose escalation on platelet function and urinary
thromboxane and prostacyclin levels in normal dogs
Pages in Study: 75
Candidate for Degree of Master of Science
Eight dogs were enrolled in a randomized, cross-over study that used optical
aggregometry and a platelet function analyzer to evaluate platelet function before and
after the administration of 5 aspirin dosages: 0.5 mg/kg q24h, 1 mg/kg q24h, 2 mg/kg
q24h, 4 mg/kg q24h and 10 mg/kg q12h. Urine 11-dehydro-thromboxane-B2 (11-dTXB2)
and 6-keto-prostaglandin-F1alpha (6-keto-PGF1alpha), were measured. Compared to pretreatment, there were significant decreases in maximum aggregometry amplitude and
increases in PFA-100 closure times for all doses except 0.5 mg/kg q24h. There was no
difference in amplitude or closure time between the 2 mg/kg, 4 mg/kg, and 10 mg/kg
q12h dosages. At 2 mg/kg q24h, 100 percent (aggregometry) of dogs were aspirin
responders. There was a significant decrease in urinary 11-dTXB2- and 6-keto-PGF1alphato-creatinine ratios with aspirin administration. An aspirin dosage of 2 mg/kg q24h
consistently inhibits platelet function in healthy dogs without decreasing prostacyclin
synthesis significantly more than lower aspirin dosages.
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INTRODUCTION
Platelet Formation and Function
Platelets are formed in the bone marrow from megakaryocytes, descendants of
large hematopoietic stem cells. As megakaryocytes mature, they will undergo
fragmentation that results in the production of platelets. [1-3] Synthesis of platelets is
controlled by a hormone, thrombopoietin, which is synthesized in the bone marrow and
smooth muscle cells. [4] Canine platelets have an average lifespan of approximately 6
days [5], which is similar to that of humans, averaging 5-7 days. [6]
Platelets play an essential role in hemostasis, a process which causes bleeding to
stop. Normal hemostasis occurs in 3 steps: platelet plug formation (primary hemostasis),
the clotting cascade (secondary hemostasis), and clot removal (fibrinolysis). Endothelial
damage and normal endothelial cell turnover is a daily occurrence. Disease processes
including infection, acidosis, hypoxemia, inflammation, and hypotension can also cause
endothelial damage.[7] After endothelial damage has occurred, the smooth muscle of the
vessel will contract causing vasoconstriction and a reduction in blood flow. Platelets will
adhere to the damaged or disrupted endothelium forming a loose platelet plug. This
process is known as primary hemostasis. The platelet plug is unstable and without
reinforcement from secondary hemostasis, it will weaken and fail to stop bleeding.
Secondary hemostasis involves the clotting cascade and eventual stabilization of the
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blood clot with fibrin cross-linking. Fibrinolysis is ultimately needed to breakdown fibrin
and dissolve the blood clots. This process is controlled mainly by plasmin.
Platelets travel inactivated within the bloodstream until called upon by damaged
endothelium to help form a thrombus. Platelet adhesion, activation, and aggregation are
the steps responsible for the initial platelet plug formation. Normal endothelial cells and
circulating platelets avoid contact due to their electronegative repulsion. But once the
vascular subendothelium is exposed, a complex process involving adhesive ligands and
receptors ensues.[8] Platelet activation occurs both before and after adhesion has taken
place. This process involves the platelet changing shape, releasing preformed granules,
and expressing molecules for aggregation.[6] Platelets will swell, becoming larger in size
and increasing their surface area, as well as forming pseudopodia. This facilitates
adherence to the injured endothelium and to other platelets.[9] Although platelets lack a
nucleus, there is still an abundance of substances contained within the platelet granules
that aid in adhesion and aggregation and further activation.[6] Alpha granules contain
platelet-derived growth factor B, fibronectin, p-selectin, transforming growth factor B, Bthromboglobulin, platelet factor 4, fibrinogen, factors V and VIII, and von Willebrand
factor (vWF).[5] Dense granules contain adenosine diphosphate (ADP), adenosine
triphosphate (ATP), histamine, epinephrine, serotonin, and calcium ions.[10] These
granules aid in platelet adhesion, promote cell-to-cell interactions, and stimulate vascular
repair.[11, 12] The alpha granules are the main secretory component within the platelet,
and contain promoters of adhesion including p-selectin, fibronectin, and vWF. P-selectin
is a cell adhesion molecule that mediates both leukocyte and platelet adhesion. P-selectin
is also capable of producing procoagulant microparticles containing active tissue factor,
2

and enhances deposition of fibrin. P-selectin is therefore involved in both primary and
secondary hemostasis.[13, 14] Activated platelets will also express surface receptors and
ligands, such as phosphatidylserine, that contribute to thrombin and fibrin formation.
Aminophospholipid phosphatidylserine is found within the inner leaflet of resting
platelets. Once the platelet is activated, phosphatidylserine will move to the platelet
surface and bind prothrombin. This will precipitate the conversion of prothrombin to
thrombin, thereby aiding in the formation of a blood clot.[15] The phosphatidylserinerich platelet surface is able to synthesize thrombin at a rate 300,000 times faster than the
fluid phase of plasma.[15] Thrombin is the most potent activator of platelets.[6]
Platelet adhesion involves binding of the platelet with the exposed
subendothelium. Shear forces as well as frictional forces applied to the endothelial layer
by the flow of blood influence these adhesive properties.[16] High shear conditions are
thought to be present in small- and medium-sized arteries, and low shear conditions are
present in large arteries and veins of any size.[17] Under high shear conditions, the
primary mechanism of adhesion involves collagen and vWF. Under low shear conditions,
platelet adhesion involves collagen, fibronectin, and laminin.[18-23] Shear forces also
influence further activation of platelets. Under high shear forces, ADP promotes platelet
activation, while under low shear forces, thromboxane A2 (TXA2) causes activation. [2426] Thrombin is active as a platelet activator under all shear conditions.[8] vWF’s
involvement in primary hemostasis includes adhesion of platelets to the endothelial wall
and conservation of factor VII.[27] vWF is synthesized by both megakaryocytes and
endothelial cells.[28] Within the endothelial cells, vWF is stored in secretory vesicles
called Weibel-Palade bodies, and within platelets and megakaryocytes it is stored within
3

alpha granules.[27] Release of vWF can be stimulated by thrombin, fibrin, vasopressin,
collagen, platelet-activating factor (PAF), epinephrine, and histamine.[28] The vWF
receptors on platelets are the integrin IIbB3 (formerly called GP IIb/IIIa) and GP Ib in
the GP Ib-IX-V complex.[27] Platelet collagen receptors include GP VI and the integrin
2B1.[29] During platelet adhesion, platelets will decelerate, marginate, and expose
these receptors to the endothelium. Once bound to the endothelium by these receptors,
platelets will undergo a conformational change that exposes the integrin IIbB3
receptor.[30] This action is key as it provides a binding site for fibrinogen.[29, 31] The
expression of the integrin IIbB3 receptor can be achieved either by the direct binding of
vWF to the receptor during adhesion or by amplification pathways initiated by
agonist/receptor binding of additional platelet receptors, such as TXA2 and ADP
receptors.[29, 32]
The last step in platelet plug formation is the aggregation of platelets. Platelet
aggregation occurs as two separate phases: primary and secondary aggregation. Primary
aggregation describes a reversible process by which platelets develop direct interactions
and undergo a shape change from a spherical to a stellate form consisting of multiple
pseudopods. If no further stimulus is received, these platelet aggregates can potentially
disperse. Once the stored contents of the alpha and dense granules of the platelet are
released, aggregation becomes irreversible and the following wave of aggregation is
termed secondary aggregation. ADP is responsible for primary platelet aggregation,
although thrombin, fibrinogen, vWF, and TXA2 are also important stimulators.[17]
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A special feature of platelets is their ability to synthesize eicosanoids, specifically
thromboxane A2. TXA2 is a major platelet aggregator and vasoconstrictor.[33] When
needed, TXA2 can be synthesized within the platelet from arachidonic acid. Arachidonic
acid (AA) is formed from the action of phospholipase A2 on the lipid membrane.[34, 35]
AA is then converted into prostaglandin H2 by the cyclooxygenase enzymes COX-1 and
COX-2, also known as prostaglandin H-synthase-1 and -2, respectively. From there,
prostaglandin H2 is then further converted into TXA2 via thromboxane synthase. TXA2
will then diffuse across membranes to exert its effects, although only for a short time,
since its half-life is approximately 30 seconds.[36] Thromboxane A2 is rapidly
metabolized into thromboxane B2, and then 11-dehydro-thromboxane B2 and 2,3-dinorthromboxane B2. These stable thromboxane metabolites are eliminated in the urine.[3739] Prostacyclin (PGI2) is another important prostaglandin produced from AA.
Prostacyclin is produced constitutively from the vascular endothelium. In contrast to
TXA2, prostacyclin inhibits platelet activation and aggregation, and causes
vasodilation.[35] Endothelial cells adjacent to those that are injured will release
prostacyclin in order to stop the platelet plug from growing excessively. Thromboxane A2
enhances platelet activation by binding with a G-protein-coupled thromboxane receptor,
while prostacyclin inhibits platelet activation by binding to the prostacyclin receptor,
activating adenylate cyclase and generating cyclic adenosine monophosphate.[9, 40]
Working together, TXA2 and prostacyclin help to balance and control hemostasis. The
other prostaglandins produced by this pathway, such as prostaglandin E2, prostaglandin
D2, and prostaglandin F2, serve key roles in mediating inflammation, renal blood flow,
and gastrointestinal wall protection.
5

There have been three COX isoforms identified in dogs. COX-1 is constitutively
expressed in most body systems, and is involved in maintenance of normal cellular
activities, platelet production of thromboxane A2, preservation and protection of gastric
mucosa, and renal blood flow.[34, 41] The COX-3 enzyme has similar catalytic activities
to COX-1, but only has about 20% of COX-1’s activity level.[42, 43] COX-2 is more
limited in distribution, being produced mainly in the brain, kidney, thymus, and vascular
endothelium, and is expressed at much lower levels compared to the other COX
enzymes.[41, 44-46] COX-2 has also been found in circulating monocytes, tissue
macrophages, and fibroblasts.[41, 44] COX-2 enzymes are also inducible by
inflammatory cytokines, macrophages, monocytes, growth factors, and endotoxin.[34, 41,
47, 48] Induction of the COX-2 enzymes occurs primarily at the post-transcriptional
level.[49] Since platelets are devoid of a nucleus, it was wrongfully believed for a long
time that only COX-1 was expressed in circulating platelets, and that COX-2 induction
within platelets could only happen at the level of the bone marrow. This belief also made
it seem more likely that the COX-1 isoform was mostly associated with thromboxane A2
production, while COX-2 was the isoform believed to be the primary stimulus for
prostacyclin production in the endothelial cells. [35, 46, 50, 51] More recent research has
shown that human and canine platelets express both COX-1 and COX-2 enzymes, with
higher levels of COX-2 being produced by immature (reticulated) platelets.[45, 50, 5254] Studies with human platelets have shown that platelets may also have the ability to
regenerate COX-1 de novo in response to external stimuli.[55]
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Inhibitors of Primary Hemostasis
Understanding the steps of primary hemostasis is essential for treatment and
prevention of thromboembolic disease. Translation of this knowledge to drug
development is paramount. Inhibitors of primary hemostasis may involve inhibition of
platelet activation, adhesion, or aggregation. Inhibitors of platelet activation include
thromboxane inhibitors, ADP antagonists (thienopyridines, nonthienopyridines), and
inhibitors of platelet signal transduction (phosphodiesterase inhibitors).[32] Although
inhibitors of platelet adhesion are in the drug development phase, none are FDAapproved at this time. Inhibitors of platelet aggregation include GP IIb/IIIa (integrin
αIIbβ3) receptor antagonists.
One of the most commonly used anti-platelet medications is aspirin
(acetylsalicyclic acid). Aspirin has been shown to be highly effective at inhibiting
platelets, at high enough doses, in both humans and dogs.[33, 56-58] Aspirin irreversibly
acetylates the hydroxyl group on a serine residue, position 529 and 516, located on the
COX-1 and COX-2 enzyme isoforms.[34, 53, 59, 60] This acetylation blocks the active
site of the COX enzyme, and prevents the conversion of AA to prostaglandin H2, thus
preventing the platelet from being able to synthesize thromboxane A2.[33, 34, 53, 61]
Since this action is irreversible, the inability to produce thromboxane A2 will persist for
the life-span of the platelet.[62] While thromboxane A2 production appears to be quite
sensitive to the inhibition of COX-1 isoforms, prostacyclin derived from the vascular
endothelium utilizes both COX-1 and COX-2 enzyme isoforms, and has been shown to
be less sensitive to the inhibitory actions of aspirin at anti-platelet doses. [33, 63, 64]
Despite an early suppression of COX-1 mediated production of prostacyclin due to the
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effects of aspirin, COX-2 dependent prostacyclin synthesis can persist.[33]
Aspirin-induced COX enzyme inhibition also affects prostaglandin E2,
prostaglandin D2, and prostaglandin F2 production, making aspirin an effective antiinflammatory medication, but also potentially causing side effects such as gastrointestinal
hemorrhage and renal failure.[39, 65-67] Furthermore, gastrointestinal damage can occur
from direct aspirin-induced mucosal damage, leading to ulceration.[66] When the
ingested aspirin enters the stomach, the acidic environment causes the aspirin to diffuse
into the mucosal cells. Within the mucosal cell, the aspirin becomes ionized and increases
the amount of back diffusion of hydrochloric acid and pepsinogen, causing mucosal
edema, inflammation, erosions, and ulceration.[66] In order to minimize this
complication, buffered and enteric-coated aspirin was designed, with hopes of inhibiting
dissolution within the stomach. This approach has been supported by studies showing
that plain aspirin is more irritating to the stomach than the buffered and enteric-coated
formulations.[68] The risk of ulceration is not entirely removed, however, as significant
gastrointestinal hemorrhage can still be see with standard anti-inflammatory doses of
enteric-coated aspirin.[66] These effects may be influenced by accumulation of entericcoated tablets within the stomach.[69] Powdered aspirin formulations at high doses
(greater than 25 mg/kg twice daily) have been administered to dogs for over a year
without any significant gastrointestinal side effects.[70] A recent human study showed
that, in contrast to the persistently high drug blood concentrations seen following
overdose with aspirin tablets, drug concentrations decline more rapidly following
ingestion of powder formulations, suggesting that prolonged absorption is unlikely with
the powder formulation of aspirin.[71] Liquid formulations of aspirin are unstable and
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become inactivated within minutes of suspension, and their systemic effects are therefore
uncertain.[72]
Another commonly used anti-platelet medication used in veterinary and human
medicine is clopidogrel, which is an ADP receptor antagonist. ADP is released from
platelet granules, and facilitates platelet aggregation. Once released, ADP interacts with
receptors P2Y1 and P2Y12, both of which are platelet G-protein-linked purinergic
receptors. Inhibition of either of these receptors will inhibit platelet function.[73, 74]
Clopidogrel has become the most commonly used ADP receptor antagonist in human
medicine.[75, 76] Clopidogrel is an irreversible inhibitor of P2Y12, which causes
permanent inhibition of circulating platelet function. Clopidogrel is classified as a
thienopyridine, and requires hepatic metabolism into its active metabolite. In the majority
of dogs, platelet function returns within 4 days of drug discontinuation, although some
individuals may take longer.[77] Clopidogrel is available in tablet form for oral once
daily administration. While other ADP receptor antagonists exist, there have not been any
veterinary studies to evaluate the use of these medications in clinical patients.
Aspirin Resistance
Anti-inflammatory or “high” dosages of aspirin (10 mg/kg twice daily) reliably
inhibit COX function and prostaglandin production in all cells that express the COX
enzyme, including platelets and vascular endothelial cells.[78] Studies have shown that
low doses of aspirin (0.5-1.0 mg/kg once daily) may inhibit platelet thromboxane
synthesis without permanently inhibiting COX function within endothelium, thus
allowing prostacyclin synthesis to persist.[37, 52, 56] These lower doses are also believed
to decrease the risk of gastrointestinal and renal side effects. These attributes are ideal
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when considering the use of aspirin for its anti-platelet properties. Unfortunately,
however, platelet inhibition does not appear consistent in all patients when lower doses
are used.[37, 52, 79] Patients that are poorly responsive to the anti-platelet effects of lowdose aspirin are termed “aspirin resistant”.[80] Aspirin resistance can be divided into two
classifications: “clinical” and “laboratory”. Clinical aspirin resistance is when
thromboembolic disease occurs in the face of low dose aspirin. Laboratory aspirin
resistance occurs when in vitro platelet function testing reveals inadequate suppression of
platelets with low doses of aspirin. Ideally, the results of these classification schemes
would agree, however discordance between classifications has been reported. The
incidence of aspirin resistance in humans ranges from 8% to 45%[33, 80] and, in healthy
dogs, the incidence is approximately 30%.[52, 79] The incidence of aspirin resistance in
canine clinic patients remains unknown.
In human medicine, a new classification scale for aspirin resistance was
developed in order to help determine the incidence of resistance, mechanisms involved,
and clinical impact. For platelet responders, collagen-induced platelet aggregation and
thromboxane formation are completely inhibited with aspirin. Type I resistance is
characterized by ineffective inhibition of platelet function and thromboxane levels with
aspirin administration, with platelet exposure to additional aspirin in vitro causing
complete inhibition of function (“pharmacokinetic resistance”). In Type II resistance,
platelets demonstrate minimal inhibition of platelet aggregation and thromboxane levels
with aspirin administration, with no further inhibition of platelet aggregation following in
vitro exposure, and only partial inhibition of thromboxane (“pharmacodynamic
resistance”). In Type III resistance, there is persistent platelet aggregation despite
10

complete thromboxane inhibition (“pseudo-resistance”). [81] Although these
classification scales have not yet been specifically applied to the dog, studies have looked
at platelet function and thromboxane levels in dogs receiving low doses of aspirin, and
reveal complex results. One study showed that only 33% of dogs treated with low dose
aspirin (1 mg/kg once daily) had impaired platelet function, with no significant
differences between responders and non-responders with regards to concurrent
thromboxane inhibition.[52] Another study showed 80% of dogs to have platelet function
inhibition with low dose aspirin, and again results were independent of thromboxane
inhibition. [79] Given these results, it is suspected that, similar to humans, dogs may
experience aspirin resistance as well.
Currently the cause of aspirin resistance remains unknown in humans and dogs,
and appears to be complex and multifactorial. Some of the mechanisms hypothesized in
human medicine include single nucleotide polymorphisms, inflammation, metabolic
syndrome, and patient compliance.[82]
Single nucleotide polymorphisms thought to be responsible for aspirin resistance
include a wide variety of genetic mutations leading to changes in biological function and
residual platelet reactivity. Proteins in human medicine that have been investigated
include integrin αIIbβ3, GP Ia/IIa and GP VI (collagen receptors), vWF, P2Y1, P2Y12,
thromboxane A2 receptor, and COX enzymes. Innate or acquired alterations in the genes
that encode these proteins may be involved in aspirin resistance. For example, previous
studies have shown that only 70% of canine platelets are responsive to thromboxane
stimulation.[83-85] A possible explanation for this finding is impaired thromboxane A2
receptor linked G proteins.[83] For these patients, other agonists may be more important
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for platelet activation, which could explain the decrease responsiveness to aspirin.[32]
Genetic polymorphisms may also cause enzymes, such as the COX enzymes, to respond
variably to aspirin.[86]
Platelets play a crucial role in the regulation of neutrophils, and they may also be
involved with amplification of inflammation. Once activated, platelets will release a
variety of inflammatory mediators, and induce expression of inflammatory mediators in
monocytes, macrophages, and granulocytes.[87] Recent studies have even suggested that
platelets can trigger a thrombotic event through their inflammatory effects, which thereby
reduces the anti-platelet effects of low dose aspirin.[88] COX-2 is inducible by
inflammation and is reportedly sensitive to the effects of low dose aspirin in humans.[89]
However, macrophages and monocytes are also important sources of thromboxane A2
during inflammation, and the COX-2 enzyme isoform within these cells appears to have a
higher threshold for aspirin inhibition compared to COX-1 isoforms.[48] Human studies
have shown that inhibition of COX-2 enzymes requires a much higher dose of aspirin
compared to COX-1 inhibition.[53] Furthermore, inflammatory cells and newly
generated platelets can synthesize increased amounts of COX-1 enzymes in an attempt to
compensate for the COX-1 that has been irreversibly inhibited by aspirin.[48] Studies
with human platelets have shown that platelets may also have the ability to regenerate
COX-1 de novo in response to external stimuli.[55] Inflammatory conditions appear to
have a significant effect on platelets and COX enzymes, and therefore may contribute to
situations in which thromboxane A2 levels are inconsistently suppressed.
Metabolic syndrome, found in human patients with diabetes mellitus,
hypertension, obesity, hypertriglyceridemia, and hypercholesterolemia, causes an
12

increased risk of vascular events.[48] Human patients with diabetes mellitus have a high
prevalence of resistance to aspirin and other anti-platelet drugs, along with persistent
thromboxane-dependent platelet activation.[90-92] Interestingly, human studies have also
found that obese populations have increased platelet activation and adhesiveness, higher
concentrations of fibrinogen, vWF, and factor VII, and reduced sensitivity to anti-platelet
drugs.[93, 94]
A few human studies have also shown that patient compliance is a cause of
aspirin resistance.[95] This could potentially translate into poor owner compliance being
a risk factor for aspirin resistance in canine patients. Additionally, enteric-coated aspirin
tablets have been shown to accumulate in the stomach of dogs, and have been deemed not
suitable for use in this species.[69, 96] Serum aspirin levels are also strongly influenced
by feeding patterns in both humans and dogs, with the presence of food significantly
decreasing the absorption of enteric-coated tablets.[96, 97]
Despite the years of experience and research with aspirin, still more research is
needed, and the exact causes of aspirin resistance remain unknown.
Assessment of Platelet Function
There are a variety of options available for testing platelet function, each with its
own unique set of features and limitations. Testing of platelet function is performed when
trying to uncover the cause of a primary hemostatic disorder, evaluate for
hypercoagulability and hypocoagulability, and evaluate the effects of anti-platelet
medications. For any of the methods involved, sample collection must be carefully
planned in advance to avoid interference with results. For example, excessively traumatic
venipuncture commonly causes platelet activation and platelet clumping (especially in
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cats), leading to pseudothrombocytopenia. Pseudothrombocytopenia can also occur due
to certain anticoagulants, such as EDTA.[98] Appropriate ratios of blood to
anticoagulants should be used. Commercially available blood collection tubes come with
a standard amount of anticoagulant and a vacuum that accepts the appropriate volume of
blood. Handling of blood samples and the time between blood draw and testing should be
carefully planned. Currently, the tests available to assess platelet function include: clot
retraction, buccal mucosal bleeding time, Platelet Function Analyzer-100®,
aggregometry, cone and plate(let) analyzers, viscoelastic coagulometers, Sonoclot®,
thromboelastography, and flow cytometry.
Clot Retraction
Clot retraction is a crude and simple test influenced by the number and function of
platelets, and the amount of fibrinogen. With this test, 5 mL of whole blood is placed into
a sterile glass tube (without any anticoagulant), a wooden applicator is inserted into the
sample, and the sample is sealed with plastic paraffin film, and incubated at 37C. The
sample is visually analyzed over the next 8-24 hours. If clot retraction is complete, serum
will be found surrounding a clot. If clot retraction does not occur, no serum will be found
surrounding the clot. The percentage of clot retraction can also be estimated by using
only 1 mL of whole blood, then 1 hour later, the amount of serum surrounding the clot is
removed and measured. The volume is then multiplied by 50 to obtain the percent clot
retraction. The normal range in animals is reported to be 25-60%.[99, 100] Clot retraction
will be reduced with anemia and prolonged with polycythemia, and is impaired by
thrombocytopenia, thrombocytopathia, and abnormalities or deficiencies with fibrinogen
and some coagulation factors.[99]
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Buccal Mucosal Bleeding Time
The buccal mucosal bleeding time (BMBT) is the most common platelet function
test available that is performed in vivo. Similar to clot retraction, a BMBT is a simple test
that can be performed easily in a general practice setting. The BMBT evaluates the time
needed to form a stable platelet plug following a standardized incision on the upper lip of
the patient. The test uses a spring-loaded template device that creates a standardized
incision. Blood is gently and carefully wicked away from the incision using filter paper.
Once the incision is made, the time is recorded until no further bleeding is observed from
the incision. Normal BMBT is less than 3 minutes in dogs.[101] Prolongation can occur
with thrombocytopenia, and with thrombocytopathias such as von Willebrand’s
disease.[101-103]
Another in vivo test that has been described is the cuticle bleeding time (also
called toenail bleeding time). This involves cutting the toenail quick to produce bleeding
while the time to clot formation is recorded. The normal reference range are reported to
be between 2 and 8 minutes.[104] The cuticle bleeding time, however, is not specific to
abnormalities of platelet number and function, since it can also be prolonged in dogs with
clotting factor deficiencies.
Platelet Function Analyzer®
The Platelet Function Analyzer® (PFA, Siemens HealthCare Diagnostics) is a
point-of-care instrument that is able to evaluate platelet function using only a small
amount of blood (800 L), and is thought of as the in vitro equivalent to a BMBT.[105,
106] The PFA machine simulates primary hemostasis by aspirating a sample of citrateanticoagulated whole blood under a high shear rate through a small aperture (150 m) in
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a collagen membrane coated with platelet agonists (for example, ADP or
epinephrine).[107, 108] This situation mimics the environment of a damaged vascular
endothelium. Closure time (CT) is the time taken for a platelet plug to form and occlude
blood flow. The maximum closure time is 300 seconds, therefore a CT of greater than
300 seconds strongly suggests platelet dysfunction. Results from a German study in dogs
found a normal CT of 47-81 seconds using collagen/ADP cartridges and 67-210 seconds
using collagen/epinephrine cartridges.[109]
The PFA can be used to evaluate inherited, acquired, or induced platelet
dysfunction in patients with normal hematocrit and platelet counts. Studies in dogs have
shown that a hematocrit (HCT) of less than 35% will significantly prolong CT. [110] CT
may also be inaccurate in patients with polycythemia (HCT >60%) or thrombocytosis
(>500 x 109 platelets/L). Dogs with heart murmurs may have a prolonged CT.[111] The
PFA has been used in dogs to evaluate for inherited thrombocytopathies such as Scott
syndrome and von Willebrand’s disease.[112, 113] The PFA has also been shown as a
sensitive indicator of aspirin-associated platelet dysfunction in both humans and
dogs.[57, 58] The collagen/epinephrine cartridge is considered ideal for drug-induced
platelet dysfunction, while the collagen/ADP cartridges are best for evaluating congenital
or acquired platelet dysfunction.[108] The original model, PFA-100®, was insensitive for
the detection of inhibitory effects of ADP antagonists.[114] However, there is now a
newer version, the Innovance PFA-200® system, that offers a highly sensitive P2Y
cartridge (Innovance PFA P2Y®) for the detection of P2Y12 receptor inhibition.[115]
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Optical Aggregometry
Optical aggregometry has the ability to evaluate platelet function using various
agonists at different concentrations using sodium-citrated platelet-rich plasma (PRP).
Depending on the situation, agonists such as collagen, ADP, epinephrine, thrombin,
arachidonic acid, and others can be used. The agonists cause activation of platelets and
exposure of the GP IIb/IIIa receptor. Fibrinogen is able to bind to this receptor and aid in
platelet aggregation. As platelet aggregation continues, the PRP suspension becomes
clearer. This change is detected using a spectrophotometer to measure light transmission.
A platelet-poor plasma (PPP) sample from the same patient is used as a control, such that
this sample represents 100% light transmission. The results are displayed as a graphed
curve, and the parameters recorded include maximal amplitude of aggregation
(percentage) and slope/rate (percentage/minute). The graph will most often show an
initial decrease in light transmission as activated platelets undergo their shape change
(from discoid to spherical). This is followed by a gradual increase in light transmission
that will eventually plateau as irreversible aggregation occurs. When weaker agonists are
used, a biphasic aggregation can be seen with an early plateau, signifying primary
aggregation, followed by a secondary curve and plateau, signifying irreversible secondary
aggregation.
Disadvantages of optical aggegometry include that it evaluates platelet
aggregation under low shear stress and does not mimic the physiologic environment in
which platelet plug formation occurs, and that it requires large volumes of blood,
technical expertise, and careful sample handling, and has limited availability. Despite
these limitations, optical aggregometry is considered to be the gold standard method for
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evaluating aspirin-induced platelet dysfunction in humans.[57, 116, 117] It can be used to
assess not only drug-induced platelet dysfunction, but also inherited and acquired causes
of platelet dysfunction. Recently, it was also demonstrated that optical aggregometry was
the most reliable test of platelet function that consistently identified dogs that responded
to an anti-platelet dosage of aspirin.[79]
In human medicine, there is also a point-of-care, cartridge based system called
VerifyNow®. This system uses citrated whole blood samples with light transmission
technology. There are various cartridges available, depending on the drug-induced effects
being evaluated. To date, there have been no studies using this method in domestic
species.
Impedance Aggregometry
Impedance aggregometry is another method of testing platelet aggregation with
the advantage of less sample preparation time than optical methods. Impedance
aggregometry uses citrated whole blood instead of PRP. This technique relies on platelets
forming a monolayer upon electrodes and changing the impedance of an electrical
current, which is detected through wires.[118] Impedance aggregometry has been shown
to correlate well with optical aggregometry in humans and, more recently, in dogs as
well.[79, 119] Impendance aggregometers graph results in a manner similar to optical
aggregometers. Aggregation is measured in maximal amplitude, but this is measured in
units of ohms.[120] The Multiplate ® whole blood platelet function analyzer, also known
as a multiple electrode impedance aggregometer (MEIA), is an impedance aggregometer
that is available for clinical use and includes five channels with disposable test cells.
Each test channel produces two aggregation curves and can be used separately, allowing
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simultaneous evaluation of platelet function using different agonists. When used to
evaluate aspirin-induced platelet dysfunction, the conventional impedance aggregometer
correlates reasonably well with optical aggregometer results, however there is poor
correlation between the MEIA and turbidimetic aggregometry, therefore it was
recommended to not use the MEIA method when evaluating aspirin responsiveness in
dogs. [79]
Cone and Plate(let) Analyzers
The DiaMed Impact-R® is a cone and plate(let) analyzer (CPA) that evaluates
platelet adhesion. Impact stands for the pneumonic “Image analysis, Monitoring, Platelet,
Adhesion, Cone and plate Technology”, with the “R” model representing its intended use
in research. This technology aims to evaluate platelet function under near physiologic
conditions, and uses image technology to measure platelets adhered and aggregated to the
well surface. The software follows an algorithm to measure average size and surface area
of platelet aggregates formed. There is limited research using this method in dogs.
Viscoelastic Coagulometers
Viscoelastic point-of-care coagulation instruments have become more popular in
both human and veterinary medicine due to their unique ability to detect hypo- and
hypercoagulability using a whole blood sample. [121] Viscoelastic analyzers measure
changes in viscosity and elasticity of a blood sample as it turns from liquid to a fibrin
clot. The most common machines used in veterinary medicine include: Sonoclot®,
Thromboelastograph (TEG), rotational thromboelastometer (ROTEM), and Haemonetics
(formly Haemoscope). These types of tests are useful for a broad understanding of the
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patient’s coagulogram, but less sensitive and specific information is provided about
platelet function. The Sonoclot® is a machine that measures changes in mechanical
impedance exerted by a probe within a blood sample. The probe senses changes in blood
viscosity or clot elasticity. The probe vibrates at 200 Hz and produces a continuous curve.
As the blood sample clots, drag increases and the probe detects increased impedance.
From this information, parameters such as activated clotting time (ACT), clot rate, and
platelet function are reported out. This method is not indicated when assessing aspirin or
clopidogrel drug-induced platelet dysfunction, however, because the methodology tests
platelet function through thrombin activation. It could, however, be used to evaluate
heparin therapy in dogs.[122]
Thromboelastography (TEG) uses a rotating plastic cylindrical cuvette (the cup)
and a stationary suspended piston (the pin). In contrast to TEG, rotational
thromboelastometry (ROTEM) uses a stationary cup and a rotary pin. TEG has a wider
application and is used more frequently. As clot formation occurs, fibrin fibrils physically
link the pin to the cup. The rotation of the cup is transmitted from the clot to the pin and
is translated into a tracing by a torsion wire. Measurements from the graph provide a
reaction time (R), K-time (K), alpha angle (), maximum amplitude (MA), and clot
stability (LY30/LY60). The reaction time is the time it takes to create a fibrin clot and
reflects PT/PTT, but does not always correlate with these values. [123, 124] The K-time
measures in minutes the time it takes from initiation of clotting for a TEG tracing to reach
a predetermined level (20 mm) of clot strength. The -angle measures in degrees the rate
of fibrin buildup and crosslinking as a function of amplitude and time. Maximum
amplitude (measured in mm) measures the widest part of the TEG tracing and represents
20

the final clot strength. Elastic shear modulus (G, in dynes/second/cm2) is calculated from
the MA and serves as another measure of clot firmness. Clot stability (LY30/LY60) is a
measurement of fibrinolysis, measuring the percent decrease in the amplitude tracing 30
and 60 minutes after the MA is determined. Results of TEG testing that could indicate
hypercoaguloability include a shorter R, steeper -angle, and increased MA.
With thromboelastography, maximum amplitude, and, to a lesser degree, K-time
and -angle, are affected by platelet function. Multiple methods of platelet activation
exist. Each sample should rest at room temperature for 30 minutes prior to analysis. [123,
125, 126] Use of whole blood is more physiologic and summates the contributions of
clotting factors, platelets, and red blood cells. TEG typically uses citrated whole blood
samples, which are re-calcified prior to activation. This method is not sensitive to platelet
inhibition from drugs such as aspirin and clopidogrel. An alternative method uses
heparinized whole blood samples. Modified TEG cups are made with a proprietary
amount of heparinase, designed to negate the effects of unfractionated heparins or lowmolecular weight heparin on tracing results. Reptilase and activated factor XIII (activator
F) are added followed by the addition of ADP (to evaluate effect of clopidogrel) or AA
(to evaluate effect of aspirin). The percentage difference between the MA with activator
F compared to the MA with activator F combined with ADP or AA is calculated to show
the reduction in platelet function. This method has been used in dogs and was shown to
be sensitive, and could potentially work for aspirin as well.[77] Although
thromboelastographic values and calculations are reportedly useful for the evaluation of
platelet function, this technology was designed to focus on formation of a fibrin clot, and
has not been well-established as a sensitive assessment of platelet function or drug21

induced platelet function.
Flow Cytometry
The principle behind the use of flow cytometry for platelet function analysis is to
test for deficiencies in platelet membrane glycoproteins and diseases of granular contents
and storage. Flow cytometry is an analytical procedure used to evaluate cell suspensions
with a laser- or impedance-based electronic detection apparatus. Using this technology,
cell counting, cell sorting, and biomarker detection can be performed. This method is
used to not only measure various cell types, but also chromosomes, proteins, or nucleic
acids attached to particles within the fluid suspension.[127] Flow cytometry instruments
have evolved to be able to measure up to 14 parameters simultaneously.[128] Platelets
can be evaluated using flow cytometry at rest and after stimulation with various
agonists.[129] This method has been used to evaluate p-selectin median florescence
intensity (MFI) as an indicator of activated platelets in dogs with immune-mediated
hemolytic anemia [130] Due to limited availability, the need for rapid sample handling,
and specialized instrumentation and expertise, this technology is under-utilized, but could
serve a vital role in future veterinary and human studies.
Future Directions
To achieve the ultimate goal of a reliable and effective prophylactic anti-platelet
therapeutic protocol for use in hypercoagulable dogs, it is essential to have a thorough
understanding of hemostasis, inhibitors of platelet function, and methods of measuring
platelet function. Although there is a relative paucity of research evaluating the efficacy
of aspirin in veterinary patients, aspirin is the most widely studied antiplatelet medication
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in humans.[131] Human studies have shown that aspirin reduces the rate of vascular
death by approximately 15%, and of nonfatal vascular events by approximately
30%.[132, 133] In humans, aspirin has been shown to be an effective antithrombotic in
conditions such as unstable and stable angina[134, 135], aortocoronary bypass surgery
[136], patients with prosthetic heart valves[137], long-term hemodialysis patients[138],
acute myocardial infarction[139], transient cerebral ischemia [140], and polycythemia
vera[141].
In veterinary medicine, few studies exist that evaluate the clinical efficacy of
aspirin. A retrospective study evaluating prognostic factors and survival rates of dogs
with immune-mediated hemolytic anemia (IMHA) found improved survival rates when
low-dose aspirin was used [142]. Although the use of aspirin in patients with IMHA is
controversial, studies support that this disease process involves platelet activation[130].
While platelet activation may not be the sole mediator leading to thromboembolism in
IMHA patients, evidence exists to support the use of antiplatelet therapies in these
patients. Another veterinary study evaluating clinical response to antiplatelet therapy was
a prospective comparison of aspirin and clopidogrel for the prevention of secondary
cardiogenic arterial thromboembolism in cats. This study showed a significant reduction
in the likelihood of secondary thromboembolism with clopidogrel administration
compared to aspirin.[143]
Clearly, there is still much to learn about the role of aspirin in veterinary
medicine, its pharmacokinetics and pharmacodynamics, the influence of comorbidities,
optimal dosages, reliable platelet function testing, and mechanisms for aspirin resistance.
Until further investigations are able to answer the multitude of questions that still exist,
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aspirin therapy will continue to be prescribed by many veterinarians. Given the low cost,
ease of administration, and availability of aspirin, it serves as an important alternative
therapy for many veterinary patients. Veterinary medicine would benefit from the
determination of an ideal therapeutic dosage of aspirin in dogs that consistently inhibits
platelet function and thromboxane A2 synthesis but that does not inhibit prostacyclin
biosynthesis. Alternatively, if there is no single dose that is ideal in all dogs, then an
individualized approach to therapy would be needed. This leads to the necessity of a
comprehensive understanding of the effects of a range of aspirin dosages in individual
patients, which will enable a more effective use of aspirin in prophylactic anti-platelet
therapeutic protocols.
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EFFECTS OF ASPIRIN DOSE ESCALATION ON PLATELET FUNCTION AND
URINARY THROMBOXANE AND PROSTACYCLIN LEVELS
IN NORMAL DOGS
Introduction
Thromboembolism is a significant complication of many commonly encountered
medical conditions in veterinary medicine, including immune-mediated hemolytic
anemia (IMHA), protein-losing nephropathies, and hyperadrenocorticism [1]. Antiplatelet therapy, including low-dose aspirin, is one of the most affordable and widely
used options for prevention of thrombus formation (thromboprophylaxis). Compared to
other thromboprophylactic drugs, dogs diagnosed with IMHA and treated with low-dose
aspirin had improved short and long-term survival times [2]. Low-dose aspirin has also
been recommended as thromboprophylaxis for dogs with glomerular disease [3, 4].
Aspirin is a cyclooxygenase (COX) inhibitor that irreversibly inhibits platelet
function. The COX enzyme converts arachidonic acid to biologically active eicosanoids,
including prostaglandins, which are necessary for normal homeostasis and hemostasis
[5]. By inhibiting COX, aspirin prevents synthesis of thromboxane A2 (TXA2) and
prostaglandins such as prostacyclin. TXA2 is primarily produced by platelets, and
triggers platelet activation and vasoconstriction [6]. Prostacyclin, in contrast, originates
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from the vascular endothelium, and inhibits platelet activation and causes vasodilation
[5].
Based on our previous work, it was determined that anti-inflammatory or “high”
dosages of aspirin (10 mg/kg twice daily) reliably inhibit COX function and
prostaglandin production in all cells that express the COX enzyme, including platelets
and vascular endothelial cells [7]. Unfortunately, high-dose aspirin may be associated
with gastrointestinal and renal side effects [8-10], which make this dose less desirable for
thromboprophylaxis [7]. In contrast to high-dose aspirin, a “low” dosage of aspirin
inhibits platelet TXA2 synthesis in humans, without permanently inhibiting COX
function within the vascular endothelium and other cells, thereby allowing prostacyclin
synthesis and vasodilation to continue, and reducing the likelihood of gastrointestinal and
renal side effects [11, 12]. Unfortunately, low-dose aspirin (0.5 to 1 m/kg once daily),
unlike high-dose aspirin, does not consistently inhibit platelet function in dogs [13-15].
Patients that are poorly responsive to the anti-platelet effects of aspirin are termed
“aspirin resistant” [16]. The incidence of aspirin resistance ranges in humans from 5% to
57% [6, 16] and, in healthy dogs, our group has previously estimated that the incidence
ranges from 19% to 56% depending on the technique used to assess inhibition of platelet
function [14, 15].
Although there are many proposed mechanisms of aspirin resistance, one
potential mechanism is aspirin underdosage. Our group has previously reported that
aspirin-associated platelet dysfunction in dogs appears to be highly dose-dependent [7,
15]. While low-dose aspirin has inconsistent and variable effects in individual dogs,
platelet function in dogs has been shown to be consistently inhibited by high doses of
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aspirin, regardless of the methods used to assess platelet function [7, 17]. Using both
PFA-100® and optical aggregometry, previous studies have demonstrated that 28% to
57% of dogs treated with low-dose aspirin (1 mg/kg, q 24h) were considered nonresponders, while all dogs were considered aspirin responders when treated with a much
higher dose (10 mg/kg, q12h) [18]. Furthermore, when canine platelets are exposed to
aspirin in vitro, at a concentration that consistently inhibits activation, platelet function is
consistently markedly inhibited [15]. The pharmacokinetic profile of low-dose aspirin in
dogs has not been evaluated, and a better understanding of drug pharmacokinetics would
clearly be beneficial when exploring mechanisms for poor response to aspirin therapy.
To date, only the anti-platelet effects of low and high doses of aspirin in dogs have been
evaluated, and the wide range of potential doses between these two extremes have not
been studied. Establishment of an optimal single “mid-range” aspirin dosage or a range
of aspirin dosages which could reliably inhibit platelet function and TXA2 synthesis
without inhibiting prostacyclin synthesis has the potential to overcome the impact of the
aspirin resistance associated with standard dosages of low-dose aspirin.
The purpose of this study was to use incremental increases in aspirin dosages to
precisely determine the dosage or dosages of aspirin that consistently inhibited platelet
function and TXA2 synthesis without inhibiting prostacyclin synthesis in normal dogs.
This study was designed to test the working hypotheses that small, incremental increases
in aspirin dosages would lead to more consistent inhibition of platelet function and TXA2
synthesis while having minimal effects on prostacyclin synthesis.
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Materials and Methods
Study Design, Animals
Eight healthy adult research Walker Hound dogs, four females and four males,
were used in this study. The dogs were not exposed to any medications or vaccines for at
least 2 weeks prior to the initiation of the study. Normal health status was established by
detection of no abnormalities on physical examination, complete blood count (including
manual platelet count), serum chemistry, urinalysis, and testing for heartworm and tickborne disease (SNAP 4Dx Plus Test, Idexx Laboratories Inc, Westbrook, ME). The
median age of the dogs was 1.5 years (range, 1 to 6.5 years), and their mean body weight
was 27.4 kg (range, 25.6 to 30.5 kg). Body weight was obtained at the beginning of the
study and used to calculate all subsequent drug doses. Animal use was approved by the
Mississippi State University Institutional Animal Care and Use Committee, and was in
compliance with the requirements of a facility accredited by the American Association
for Accreditation of Laboratory Animal Care.
In a five way, randomized, cross-over study, the dogs were separated into one of
five groups, with each group given different oral dosages of aspirin (Aspirin, Major
Pharmaceuticals, Livonia, MI): 0.5 mg/kg q24h, 1 mg/kg q24h, 2 mg/kg q24h, 4 mg/kg
q24h or 10 mg/kg q12h. Aspirin doses were compounded into capsules by the
Mississippi State University College of Veterinary Medicine Pharmacy. All drugs were
administered orally for 7 days, followed by at least a 14 day washout period between
dosing. After this washout period, the dogs switched groups, and the study was
continued until all dogs had received each aspirin dosage.
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Prior to aspirin therapy (day 0) and after one week of drug administration (day 7),
blood samples were collected for platelet function analysis (optical aggregometry
and point-of-care platelet function analyzer), and urine samples were collected to
measure urinary 11-dehydro-thromboxane B2 (11-dTXB2) and 6-ketoprostaglandin F1α (6-keto-PGF1α) concentrations (stable metabolites of TXA2 and
prostacyclin, respectively). Blood and urine samples collected on Day 7 were
taken one hour after aspirin administration. Blood samples were collected via
jugular venipuncture with a 20-gauge needle directly into a 4.5 mL vacutainer
tube containing 3.2% sodium citrate anticoagulant. Urine was collected via
cystocentesis using a 22-gauge 1.5-inch needle, and samples were stored at -80oC
for later analysis.
Optical Aggregometry
To harvest platelet-rich plasma (PRP), whole blood collected into 3.2% sodium
citrate was centrifuged at 1,200 g at room temperature for 3 minutes. The PRP
supernatant was collected, and the remaining blood sample was centrifuged at 1,800 g at
room temperature for 8 minutes to create platelet-poor plasma (PPP).
A two channel light transmission (optical) platelet aggregometer (Chronolog 700
Whole Blood/Optical Lumi-Aggregometer, Chronolog Corporation, Haverton, PA) that
allowed for two samples to be evaluated concurrently was used to analyze platelet
aggregation in PRP. Samples were analyzed based on the manufacturer’s standard
guidelines (Chrono-Log 700 manual. Havertown, PA: Chrono-Log Corp, 2006). Briefly,
450 µl of PRP was transferred into a glass cuvette containing a siliconized magnetic stir
bar, and 500 µl of PPP was placed into a cuvette without a stir bar. Samples were
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incubated at 37oC for 5 minutes and then placed into the aggregometer, and stable
baseline values for minimal (PRP) and maximal (PPP) aggregation were obtained
(assigned values of 0% and 100% aggregation, respectively). Platelet numbers within the
PRP were not adjusted to a standardized count by dilution with PPP prior to analysis,
based on recommendations put out by the International Society of Thrombosis and
Haemostasis Platelet Physiology and Scientific and Standardization Committee [19-22].
Collagen, 10 μg/mL, was then added to the PRP, and aggregation was monitored for 12
minutes. The maximal percentage aggregation was calculated and recorded using
computer software (AGGRO/LINK 8, Chronolog Corporation, Haverton, PA). Platelet
function analysis was performed within 4 hours of collection.
Platelet Function Analysis
A commercial point-of-care whole blood platelet function analyzer (PFA-100®,
Siemens Healthcare Diagnostics, Deerfield, IL) that has previously been evaluated for
use in dogs [23-26] was used to analyze platelet function. This platelet function analyzer
stimulates platelet function with several agonists under high shear forces and measures
the closure time, in seconds, needed to form a platelet plug and inhibit blood flow. The
manufacturer’s cut-off time for the instrument is 300 seconds.
The instrument was used according to manufacturer’s instructions. Briefly, blood
samples were gently mixed, and kept at room temperature without agitation until
analysis. For analysis, 800 l of whole blood was transferred into either a collagen/ADP
cartridge (PFA Collagen/ADP Test Cartridge, Siemens Healthcare Diagnostics, Duluth,
GA) (performed initially to establish normal platelet function) or collagen/epinephrine
cartridge (PFA Collagen/EPI Test Cartridge, Siemens Healthcare Diagnostics, Duluth,
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GA) (used throughout the study to assess aspirin-associated platelet dysfunction) and
analyzed. Two collagen/epinephrine cartridges were analyzed at each time point for all
dogs, and the closure times were averaged. Platelet function analysis was performed
within 2 hours of collection.
Aspirin Responsiveness
Based on our previously published criteria used for dogs [15], each dog was
classified as either an aspirin responder or an aspirin non-responder. For optical
aggregometry, a dog was considered to be an aspirin responder if there was a greater than
25% reduction in the percentage aggregation at maximum amplitude compared to day 0
values. For the whole blood platelet function analyzer, a dog was considered to be an
aspirin responder if the closure time was >300 seconds.
Urine 11-dehydro-thromboxane B2 Analysis
Urinary 11-dTXB2 concentration was analyzed using an enzyme-linked
immunosorbent assay kit (11-dehydro-thromboxane B2 EIA kit-Monoclonal, Cayman
Chemical Co, Ann Arbor, MI) that has been previously validated in the dog [13]. Prior to
analysis, urine samples were thawed to room temperature, then handled according to the
manufacturer’s instructions. Samples were analyzed in triplicate on a plate reader
(SpectraMax M5 Multi-Mode Microplate Reader, Molecular Devices, Sunnyvale, CA).
Results were averaged, and reported as picograms per milliliter of urine. Urine creatinine
concentration was measured using a biochemistry analyzer (ACE Alera® 201 Clinical
Chemistry System, Alfa Wasserman, Inc.) in order to calculate a urinary 11-TXB2-tocreatinine ratio.
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Urine 6-keto-prostaglandin F1α Analysis
Urinary 6-keto-PGF1α concentration was analyzed using an enzyme-linked
immunosorbent assay kit (6-keto-prostaglandin-F1α ELISA, Cayman Chemical Co, Ann
Arbor, MI) that has undergone extensive analytic validation by the manufacturer, and has
been used previously in dogs [27]. Using a similar technique as previously described
with urinary 11-dTXB2, urinary 6-keto-PGF1α were analyzed according to the
manufacturer’s instructions. Samples were analyzed in triplicate, averaged, and reported
in picograms per milliliter of urine. Urine creatinine concentration was measured to
calculate a urinary 6-keto-PGF1α-to-creatinine ratio.
Statistical Methods
Mixed models using PROC MIXED in a computer software program (SAS for
Windows 9.4, SAS Institute, Inc., Cary, NC) were fit for each outcome that included
dose, sample and the dose*sample interaction as fixed effects. Dog identity within run
and run were included as random effects with variance components covariance structure.
An LSMEANS statement was used to make comparisons among levels of significant
main effects. If the interaction term was significant, differences in least squares means
between each of the levels of one variable were calculated for each level of the other
variable in the interaction using an LSMESTIMATE statement. If there were significant
main effects with more than two levels or significant interaction terms, the simulate
option in the LSMEANS or LSMESTIMATE statements was used to adjust p-values to
account for the effect of multiple comparisons. The distribution of the conditional
residuals was evaluated for each outcome to ensure the assumptions of normality of the
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residuals and heteroscedasticity had been met. An alpha level of 0.05 was used to
determine statistical significance for all methods.
Results
Optical Aggregometry
The mean optical aggregometry maximum amplitude for all aspirin dosages on
days 0 and 7 are represented in Figure 2.1. There was no significant difference in the
maximum amplitude for the 5 aspirin dosages on day 0 (pre-treatment). When compared
to day 0, there was a significant decrease in maximum amplitude on day 7 for 1 mg/kg
q24h (p=0.0259), 2 mg/kg q24h (p<0.0001), 4 mg/kg q24h (p<0.0001), and 10 mg/kg
q12h (p<0.0001). On day 7, the maximum amplitude for 0.5 mg/kg q24h was
significantly greater than for 2 mg/kg q24h (p=0.0004), 4 mg/kg q24h (p=0.0007), and 10
mg/kg q12h (p=0.0003). There was no difference in maximum amplitude among the 2
mg/kg q24h, 4 mg/kg q24h, and 10 mg/kg q12h dosages.
Two dogs were considered aspirin responders when treated with 0.5 mg/kg q24h.
When treated with 1 mg/kg q24h and 4 mg/kg q24h, 6 dogs were considered to be aspirin
responders. All dogs were considered to be aspirin responders when treated with 2
mg/kg q24h and 10 mg/kg q12h. One dog was classified as an aspirin responder with all
five aspirin dosages.
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Figure 2.1

Maximum amplitude (percentage) of aggregation via optical aggregometry
in 8 dogs treated with different oral dosages of aspirin: 0.5 mg/kg q24h, 1
mg/kg q24h, 2 mg/kg q24h, 4 mg/kg q24h, and 10 mg/kg q12h.

The graph demonstrates the mean +/- SEM. Sample points labeled * illustrate significant
differences (p<0.05) from the corresponding dosage on day 0 values. Within day 7,
samples labeled † were significantly different (p<0.05) from the maximum amplitude of
0.5 mg/kg q24h.
Platelet Function Analysis
The mean closure times for all aspirin dosages on days 0 and 7 are represented in
Figure 2.2. There was no significant difference in the closure time for the 5 aspirin
dosages on day 0 (pre-treatment). When compared to day 0, there was a significant
increase in closure times on day 7 for 1 mg/kg q24h (p=0.0002), 2 mg/kg q24h
(p=0.0002), 4 mg/kg q24h (p<0.0001), and 10 mg/kg q12h (p<0.0001). On day 7, the
closure times for 0.5 mg/kg q24h were significantly greater than 2 mg/kg q24h
(p=0.0388), 4 mg/kg q24h (p=0.0002), and 10 mg/kg q12h (p=0.0006). There was no
difference in closure times among the 2 mg/kg q24h, 4 mg/kg q24h, and 10 mg/kg q12h
dosages.
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None of the dogs treated with 0.5 mg/kg q24h were considered to be aspirin
responders. Two dogs were considered to be aspirin responders when treated with 1
mg/kg q24h and 5 dogs were classified as aspirin responders when treated with 2 mg/kg
q24h. When treated with 4 mg/kg q24h and 10 mg/kg q12h, 7 dogs were considered to
be aspirin responders.
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Figure 2.2

Whole blood point-of-care platelet function analyzer (PFA-100) closure
times (collagen/epinephrine cartridge) in 8 dogs treated with different oral
dosages of aspirin: 0.5 mg/kg q24h, 1 mg/kg q24h, 2 mg/kg q24h, 4 mg/kg
q24h, and 10 mg/kg q12h.

The graph demonstrates the mean +/- SEM. Sample points labeled * illustrate significant
differences (p<0.05) from the corresponding dosage on day 0 values. Within day 7,
samples labeled † were significantly different (p<0.05) from the closure time of 0.5
mg/kg q24h.
Urine 11-dehydro-thromboxane B2 Analysis
The urine 11-dTXB2-to-creatinine ratio for all aspirin doses on days 0 and 7 are
represented in Figure 2.3. Compared to day 0, there was a significant (p=0.0003)
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decrease in the 11-dTXB2-to-creatinine ratio on day 7 for all aspirin dosages. However,
there was no significant dose dependent decrease in the 11-dTXB2-to-creatinine ratio for
all doses.
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Figure 2.3

Urine 11-dehydro-TXB2:creatinine ratio seen in 8 dogs treated with
different oral dosages of aspirin: 0.5 mg/kg q24h, 1 mg/kg q24h, 2 mg/kg
q24h, 4 mg/kg q24h, and 10 mg/kg q12h.

The graph demonstrates the mean +/- SEM. There was no dose effect on the urine 11dehydro-TXB2:creatinine ratio, and day 7 values were significantly different (p<0.05)
than day 0 values.
Urine 6-keto-prostaglandin F1α Analysis
The urine 6-keto-PGF1α-to-creatinine ratio for all aspirin doses on days 0 and 7
are represented in Figure 2.4. Compared to day 0, there was a significant (p=0.0075)
decrease in the 11-dTXB2-to-creatinine ratio on day 7 for all aspirin dosages. However,
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there was no significant dose dependent decrease in the 6-keto-PGF1α-to-creatinine ratio
for all doses.

Figure 2.4

Urine 6-keto-prostaglandin F1α:creatinine ratio seen in 8 dogs treated with
different oral dosages of aspirin: 0.5 mg/kg q24h, 1 mg/kg q24h, 2 mg/kg
q24h, 4 mg/kg q24h, and 10 mg/kg q12h.

The graph demonstrates the mean +/- SEM. There was no dose effect on the urine 6keto-prostaglandin F1α:creatinine ratio, and day 7 values were significantly different
(p<0.05) than day 0 values.
Discussion
The ideal dose of aspirin that consistently inhibits platelet function in dogs, while
minimizing any drug-associated side effects, is unknown. Currently used standard low or
anti-platelet dosages (0.5-1 mg/kg/day) of aspirin, however, do not reliably inhibit
platelet function [13-15]. Platelet function in dogs will, in contrast, be consistently
inhibited by high dosages of aspirin [17], suggesting that, if dogs are treated with high
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enough doses of aspirin, there is an increased likelihood of inhibition of platelet function.
Unfortunately, as the aspirin dosage increases, so does the risk of undesirable inhibition
of prostacyclin, and of aspirin-induced side effects. The data reported in the current
study suggest that a modified “low” dosage of aspirin (2 mg/kg q24h) will consistently
inhibit canine platelet function in normal dogs, without the need to resort to much higher
standard anti-inflammatory aspirin dosages of 10 mg/kg twice daily.
In humans, optical aggregometry is considered to be the gold standard method for
evaluating aspirin-induced platelet dysfunction [23, 28, 29]. Recently, our group
demonstrated that optical aggregometry was the most reliable test of platelet function that
consistently identified dogs that responded to an anti-platelet dosage of aspirin [15]. In
the current study, compared to pre-treatment values, all aspirin dosages except the very
lowest dosage (0.5 mg/kg q24h) significantly decreased platelet aggregation after 7 days
of drug administration. On day 7, there was no significant difference in the mean platelet
amplitude among the aspirin dosages, except at the lowest dosage. Additionally, on day
7, compared to the 0.5 mg/kg q24h dosage, there was a significant decrease in platelet
aggregation for the 2 mg/kg q24h, 4 mg/kg q24h, and 10 mg/kg q12h dosages, but not for
the 1 mg/kg q24h dosage. These results are consistent with a dose-dependent decrease in
platelet aggregometry that reaches maximal effect at an oral aspirin dosage of 2 mg/kg
once daily.
Recently, using optical aggregometry, canine aspirin responsiveness was defined
as a greater than 25% reduction in the percentage aggregation at maximum amplitude
following aspirin treatment, compared to pre-aspirin values [15]. Using this definition,
our group had demonstrated that, when aspirin was administered to dogs at an oral
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dosage of 1 mg/kg once daily for 7 days, approximately 80% of the dogs were classified
as aspirin responders. These previous results were similar to the results reported here, in
that when dogs were administered the same dose of aspirin for 7 days, 75% were
considered to be aspirin responders. In contrast, in this current study, when treated with a
2 mg/kg once daily aspirin dosage, all dogs were considered to be aspirin responders, a
rate of aspirin responsiveness that was identical to that seen with the high antiinflammatory dosage of aspirin (10 mg/kg q12h). These results suggest that an aspirin
dosage of 2 mg/kg once daily will provide consistent aspirin-induced platelet dysfunction
in normal dogs, and that higher dosages of aspirin may not provide additional antiplatelet benefits. Although the 2 mg/kg q24h and 10 mg/kg q12h dosages achieved 100%
aspirin responsiveness, only 6/8 (75%) of the dogs receiving the 4 mg/kg q12h dosage
were considered aspirin responsive. In the two dogs considered non-responsive at this
dose, platelet function was inhibited (by 7% and 20%) compared to pre-aspirin values,
but did not achieve the 25% reduction required for classification as aspirin responders.
When treated with the 10 mg/kg q12h dose, these same two dogs had the least reduction
in aggregometry amplitude (73% and 43%) compared to an average of 98% reduction for
the other six dogs. These findings suggest that additional pharmacodynamic effects,
other than dosage, could influence the anti-platelet effects of aspirin.
Similar to previous studies in dogs [14, 23, 25], this study demonstrated that
aspirin-induced platelet dysfunction could be determined by using a commercial whole
blood point-of-care platelet function analyzer (PFA-100) with a collagen/epinephrine
cartridge. Our group has previously reported that, compared to optical aggregometry, the
PFA-100 is less reliable at determining drug responsiveness in dogs receiving aspirin
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[15]. In our previous studies using the PFA-100 in dogs treated with aspirin at a dosage
of 1 mg/kg once daily for 7 days, only 33% to 44% of dogs were classified as aspirin
responders [14, 15] and, when the same aspirin dosage was used in the current study,
25% of dogs were considered to be aspirin responders. Also in this study, at the same
aspirin dosage of 1 mg/kg daily, 75% of the dogs were considered to be aspirin
responders based on aggregometry results. This discrepancy was not unexpected because
the PFA-100, although it is often used to clinically evaluate platelet function in dogs
receiving aspirin, has been previously reported by this group to markedly overestimate
the degree of aspirin resistance compared to optical aggregometry [15]. When receiving
aspirin at a dosage of 2 mg/kg once daily, approximately 63% of the dogs in this study
were classified as aspirin responders by the PFA-100, which is only slightly below the
88% of patients that were classified as aspirin responders when treated with the higher
two aspirin dosages (4 mg/kg once daily, and 10 mg/kg twice daily). Based on PFA-100
results alone, an aspirin dosage of 4 mg/kg once daily would appear to be sufficient to
maximize drug anti-platelet effects. However, when PFA results are considered
concomitantly with aggregometry results, an aspirin dosage of 2 mg/kg may be sufficient
overcome aspirin resistance, especially considering that aggregometry is more sensitive
than the PFA-100 to the anti-platelet effects of aspirin.
During this study, mild transient gastrointestinal side effects were noted in some
dogs with the administration of the anti-inflammatory high dosage of aspirin, 10 mg/kg
twice daily, but no side effects were noticed with any of the lower aspirin dosages. This
study was, however, not designed to specifically monitor for aspirin-induced
gastrointestinal lesions such as gastric ulceration or erosions, and additional studies
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would be warranted to further explore the potential gastrointestinal side effects of using
aspirin at dosages greater than 0.5-1 mg/kg daily. Furthermore, since low-dose aspirin is
commonly administered concurrently with glucocorticoids to dogs with IMHA,
additional studies would be necessary to determine the gastrointestinal side effects of a
slightly increased “low” aspirin dosage, such as 2 mg/kg once daily, during concurrent
glucocorticoid administration.
In previous studies in humans and dogs, the stable TXA2 metabolite 11-dehydrothromboxane B2 has been used as an indicator of aspirin-induced inhibition of
thromboxane synthesis [30, 31]. A second stable TXA2 metabolite, 2,3-dinorthromboxane-B2 (2,3-dinor-TXB2), is also present in the urine of dogs, and can also serve
as a surrogate marker of thromboxane synthesis [13]. A previous study demonstrated
that, compared to 11-dTXB2, canine urinary 2,3-dinorTXB2 concentrations were a more
sensitive indicator of aspirin-induced thromboxane inhibition [13]. Unfortunately, an
assay for 2,3-dinorTXB2 in dogs was unavailable at the time of this study. However,
although the urine TXA2 metabolite assay used in this study has been published to not be
the most sensitive indicator of aspirin-induced thromboxane inhibition, our previous
work has shown that this assay is still sufficiently sensitive to detect a decrease in
thromboxane synthesis during aspirin administration [14]. The results of the current
study revealed that the administration of aspirin at any dosage caused a significant
decrease in thromboxane synthesis, but there was no detectable dose-dependent
relationship between the aspirin dose and thromboxane synthesis. The results reported
here were similar to results from our previous work performed in dogs, in that aspirininduced reductions in thromboxane synthesis were not dependent on drug dosage [7, 14,
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15, 17]. The current study suggests that the inhibition of thromboxane synthesis seen
with an aspirin dosage of 2 mg/kg once daily is similar to that seen with the traditional
lower anti-platelet dosages of 0.5 and 1 mg/kg once daily, and that an increase in aspirin
dosages beyond 2 mg/kg once daily will not cause additional inhibition in thromboxane
synthesis. However, it is conceivable that a more sensitive assay, such as the 2,3dinorTXB2 assay, might be able to detect more subtle variations in thromboxane
synthesis, particularly considering that the current study detected a possible subtle (and
not statistically significant) dose-dependent decrease in urine 11-dTXB2 concentrations at
higher aspirin dosages (Figure 3).
Prostacyclin (prostaglandin I2), after being synthesized by the vascular
endothelium, has a short half-life, and will quickly be converted into stable metabolites,
including 6-keto PGF1α and 2,3 dinor-6-keto PGF1α, which can be used as surrogate
markers of prostacyclin synthesis [27, 32-34]. One proposed benefit of low-dose aspirin
is that lower dosages will irreversibly inhibit platelet thromboxane synthesis without
permanently inhibiting COX function in the vascular endothelium, allowing prostacyclin
synthesis to continue. Anti-inflammatory high dosages of aspirin, in contrast, are
purported to inhibit COX function and prostaglandin synthesis in both platelets and the
vascular endothelium [11, 12]. The ideal anti-platelet dosage of aspirin would reliably
inhibit platelet function, but would not inhibit prostacyclin synthesis. The results
reported here, however, demonstrated that the administration of aspirin to dogs at any
dosage leads to a decrease in prostacyclin synthesis. Similar to the findings with urinary
thromboxane metabolites, there was no detectable dose-dependent relationship between
aspirin dose and urinary prostacyclin metabolites. These results suggest that, although
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prostacyclin synthesis is reduced somewhat even at the lowest evaluated dosage of
aspirin, the incremental increases in aspirin dosages needed to progressively inhibit
platelet function will not further reduce the beneficial properties of residual prostacyclin
synthesis. A slightly increased “low” aspirin dosage of 2 mg/kg once daily, therefore,
would be expected to consistently inhibit platelet function while still maintaining
prostacyclin concentrations comparable to those seen with traditional lower anti-platelet
dosages of aspirin. Again, as with urine 11-dTXB2, this study detected a possible subtle
(and not statistically significant) dose-dependent decrease in urine 6-keto-PGF1α
concentrations at higher aspirin dosages. Therefore, the inclusion of a larger number of
dogs in the study could conceivably have elucidated a statistically significant dosedependent decrease in 6-keto-PGF1α concentrations.
One limitation of the study is that there are no standard techniques that are
consistently used to evaluate aspirin responsiveness. The platelet function assays and
classification system used in this study are similar to previous studies that have evaluated
aspirin-induced platelet dysfunction [15, 28]. However, other studies have used different
methodologies and protocols to assess aspirin-induced platelet dysfunction [35], and this
variability in methods does not allow for ready comparison between studies.
Additionally, the dogs used in the study were healthy, and these results may not be
directly applicable to prothrombotic patients. Finally, the dogs used in this study were
only given aspirin for one week, whereas low-dose aspirin is commonly administered
long term, and it is as yet unknown how canine platelet function and eicosanoid synthesis
will respond to chronic aspirin administration.
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The role of aspirin therapy for thromboprophylaxis is controversial in veterinary
medicine. The use of anti-coagulant therapy is commonly used for thromboprophylaxis
and might be the more effective therapies for the prevention of venous thromboembolism
because platelets are not the primary facilitator of thrombus formation in veins.
However, platelets can still contribute to the formation and acceleration of venous
thrombosis. For example, Weiss et al demonstrated that dogs with IMHA will have an
increase in activated circulating platelets (Weiss et al., 2006). Additionally, dogs with
IMHA treated with 0.5 mg/kg q24h of aspirin had a better short and long-term survival
times compared to other anti-coagulant therapy. Recently, a study evaluated the safety of
aspirin, clopidogrel, or aspirin and clopidogrel in dogs with IMHA. Although the study
was underpowered to determine the most effective treatment option, when anti-platelet
therapy was used as the sole thromboprophylaxis therapy, only 2 of 24 dogs developed a
suspected thromboembolism (Mellett et al., 2011). Finally, aspirin and other anti-platelet
therapies are readily available, inexpensive, easy to administer long term, and do not
require routine assessment of coagulation to ensure appropriate inhibition. Therefore,
aspirin or other anti-platelet therapies are commonly administered to patients at risk for
formation of thromboembolism.
As discussed, low-dose aspirin is commonly used in an attempt to prevent
thrombus formation in prothrombotic dogs but, at traditional anti-platelet dosages of 0.5
to 1 mg/kg once daily, platelet function appears to be inconsistently inhibited. Higher
aspirin dosages may therefore be needed to provide appropriate platelet inhibition. As
the aspirin dosage increases, however, so do the likely risks of aspirin-induced side
effects and inhibition of prostacyclin. The results of this study suggests that, in healthy
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dogs, an oral aspirin dosage of 2 mg/kg once daily will consistently and adequately
inhibit platelet function without decreasing the degree of prostacyclin synthesis
significantly more than lower aspirin dosages. Additional studies will be required to
determine if this higher aspirin dosage is associated with an increased risk of adverse
drug effects.
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CONCLUSION
Using optical aggregometry, our study found that 100% of dogs were aspirin
responders using a 2 mg/kg once daily aspirin dosage. For hypercoagulable conditions
that include increased platelet activity, this newly recommended low dose rate of aspirin
could improve overall efficacy and produce significantly improved survival times.
Currently, there are no clear protocols for treatment or prevention of thromboembolism in
dogs. Furthermore, despite treatment with various inhibitors of hemostasis, patients
continue to experience thromboembolic events with life-threatening side effects. Lack of
information regarding the causes for hypercoagulability, proper drug doses, and effective
monitoring are undoubtedly related to the poor efficacy of these treatments. Depending
on the specific disease pathophysiology, inhibitors of primary hemostasis, inhibitors of
secondary hemostasis, or a combination of both, may be needed in order to prevent
thrombosis and improve survival rates. While some studies report improved survival with
certain hemostasis inhibitors [1-3], we are still lacking controlled studies with direct
comparison between various treatment options.
Based on the results of our current study, we recommended a 2 mg/kg once daily
dosage of aspirin for thromboprophylaxis. However, since only 6/8 dogs with a 4 mg/kg
once daily dosage were considered aspirin responders, a superior approach to
thromboprophylaxis may be to start at a 2 mg/kg/day dosage and use individualized dose
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adjustments based on serial platelet function testing, ideally platelet aggregometry. In
clinical situations where platelet aggregometry cannot be performed, PFA-100® could be
used as an alternative. Baseline and recheck evaluation could be recommended one week
after starting aspirin therapy, and one week after any dose changes. If either test failed to
show aspirin responsiveness, the aspirin dose could be increased incrementally until the
desired affect is reached. Prior to initiating a treatment protocol of this nature, additional
studies are recommended in order to understand the potential gastrointestinal side effects
at higher aspirin doses.
One concern with using aspirin for thromboprophylaxis is the inability to
standardize and optimize the methods for evaluating platelet function. Optical
aggregometry is considered to be the gold standard method for evaluating aspirin-induced
platelet dysfunction in humans.[4-6] It was also recently demonstrated that optical
aggregometry was the most reliable test of platelet function that consistently identified
dogs that responded to an anti-platelet dosage of aspirin.[7] While we currently accept
optical aggregometry as the gold standard when evaluating aspirin-induced platelet
dysfunction in dogs, there is uncertainty both in human and veterinary medicine as to
whether or not this is actually the most appropriate methodology.
Our study chose, as well as utilizing optical aggregometry, to include other
methods of platelet function, such as the PFA-100®, because of the user-friendly
technique and increased availability of these methods. At 2 mg/kg q24h, 100% of dogs
were aspirin responders using optical aggregometry, while only 62.5% of dogs were
aspirin responders using PFA-100®. Relying solely on PFA-100®, there would have been
an additional 37.5% of dogs classified as non-responders. Utilizing the PFA-100® to
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assess platelet function is therefore questionable, and could lead to inappropriate doses
being used in patients. Additionally, while the PFA-100® may potentially provide
information about increased activity of platelets, it is uncertain whether or not shortened
closure times represents increased platelet activity and hypercoagulability. One
alternative method may be the VerifyNow® system, a point-of-care analyzer which has
received approval by U.S. Federal Drug Administration for assessing platelet function in
humans. The sensitivity of the VeryifyNow system for detecting aspirin-induced
inhibition of platelet function in human medicine has been reported to vary widely, from
38% to 95%. [5, 8, 9] The correlation between VerifyNow and light transmission
aggregometry with arachidonic acid as an agonist was found to be poor in human patients
with stable coronary artery disease receiving aspirin [5], whereas in healthy patients it
was shown to have good correlation.[10] In studies where high sensitivities of the
VerifyNow system were reported for aspirin-induced platelet dysfunction, it was
suggested that this method may optimal. Of course, additional studies are needed in order
to better understand the utility of this method, particularly in dogs. Identifying a method
that is sensitive and correlates well with light transmission aggregometry, but is more
readily available and user friendly, would have the potential to provide an enormous
amount of information in veterinary clinical patients receiving aspirin.
Evaluation of blood acetylsalicyclic acid and salicyclic acid levels may help to
solve some of the mystery involved with finding the ideal dose of aspirin to inhibit
platelets. Early human studies evaluating aspirin, however, showed an absence of a
definable relationship between plasma acetylsalicyclic acid and its effects.[11] Canine
studies attempting to correlate anti-inflammatory effects or analgesic properties of aspirin
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with blood acetylsalicyclic acid levels have also shown that onset and duration of
analgesia with either oral or intravenous routes of administration could not be correlated
to plasma levels of acetylsalicyclic acid.[12] This was likely because acetylsalicyclic acid
is rapidly converted into salicyclic acid. Pharmacokinetic studies evaluating plasma
salicyclate levels in dogs have shown marked individual variations in blood levels.[13,
14] A simple and sensitive analytical method using liquid chromatography-tandem mass
spectrometry for determination of acetylsalicylic acid (aspirin) and its major metabolite,
salicylic acid, in animal plasma has been developed and validated, and could be used in
pharmacokinetic studies.[15] While many human studies incorporate acetylsalicyclic acid
and salicyclic acid assays into their pharmacodynamic evaluations of platelet inhibition,
similar studies in veterinary patients are lacking. A human study used high-performance
liquid chromatography to compare plasma levels of acetylsalicyclic acid and salicyclic
acid when two doses of aspirin were administered (160 mg/day vs 80 mg/day). [16]
Combining this pharmacokinetic information with pharmacodynamic assays (inhibition
of platelet thromboxane generation and urinary excretion of thromboxane and
prostacyclin metabolites) allowed for a more complete evaluation of these two doses.
Given the short half-life of acetylsalicyclic acid, and evidence that only platelets exposed
to non-hydrolyzed acetylsalicyclic acid are inactivated, other delivery methods for
acetylsalicyclic acid have been developed to provide coverage over a full 24 hour
interval.[17-22] For example, one study compared the pharmacokinetics and
pharmacodynamics of once daily immediate-release aspirin to an extended-release
formulation of aspirin.[23] This study concluded that both aspirin formulations showed
dose-dependent anti-platelet activity and that, compared to the immediate-release
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formulation, the extended-release formulation released active drug more slowly, resulting
in prolonged absorption and lower systemic drug concentrations. The data from this study
suggested a higher dose (162.5 mg) of extended-release aspirin is needed to achieve the
same pharmacodynamic response as immediate-release aspirin 81 mg in steady state.
Similar to human studies, investigating these factors in veterinary medicine could also
help to better understand the pharmacokinetics and pharmacodynamics of aspirin in the
dog, and could improve pharmacological and clinical success of this drug.
While it seems likely that the adjusted low-dose of aspirin (2mg/kg q24h) will
improve inhibition of platelets in healthy dogs, it is unknown whether the same response
will be obtained in patients with hypercoaguable states. Activation of platelets has been
demonstrated in dogs with diseases such as IMHA, Babesia rossi infection, and
endotoxemia, and in critically-ill dogs.[24-27] However, there have been no studies that
have reported the impact of anti-platelet therapy on platelet function in dogs with
diseases causing hypercoagulability associated with platelet hyperactivity.[28] This
leaves some clinicians skeptical of the usefulness of aspirin in canine clinic patients,
although the low-cost and ease of treatment continues to be a driving force for its use.
The next step moving forward involves elucidating which hypercoagulable diseases
involve platelet activation, studying platelet function in dogs with diseases known to have
increased platelet activity contributing to thromboemboli while receiving anti-platelet
therapy, and comparing outcome and survival in these patients compared to those without
anti-platelet therapy.
Increasing the recommended low-dose of aspirin to 2 mg/kg q24h may increase
the risk of gastrointestinal upset and hemorrhage. Significant gastrointestinal hemorrhage
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has been detected in dogs receiving the standard anti-inflammatory dose of aspirin (10-35
mg/kg q8-12h). [29-35] The risk of gastrointestinal damage with low-dose aspirin has not
been thoroughly evaluated in dogs, but few studies have suggested that these doses (0.5-1
mg/kg/day) will decrease the likelihood of gastrointestinal side effects.[2, 36-38]. An
increased risk of gastrointestinal ulceration or hemorrhage when aspirin is used in
combination with prednisone or other glucocorticoid medications has also been theorized.
Glucocorticoids are thought to induce gastrointestinal ulceration by the inhibition of
phospholipase A.[39-41] In addition, glucocorticoids have been shown to decrease
healing of gastrointestinal ulcers by altering the composition of gastric mucus, decreasing
gastric mucosal cell turnover, inhibiting capillary and fibroblast proliferation, and
enhancing collagen breakdown.[39, 40, 42-44]. While studies have shown that
dexamethasone and extremely high doses of methylprednisolone cause gastrointestinal
ulceration, few studies have evaluated the gastrointestinal effects of prednisone or
immunosuppressive doses of prednisone in dogs.[45, 46]
Ultimately, the risk of gastrointestinal ulceration and hemorrhage associated with
low-dose aspirin and immunosuppressive doses of prednisone has not been evaluated in
canine clinic patients separately or in combination, or long-term. In healthy dogs, one
study did evaluate the effects of prednisone (2 mg/kg/day) alone and in combination with
low-dose aspirin (0.5 mg/kg/day) on the gastroduodenal mucosa.[47] This study found
that the concurrent use of prednisone and low-dose aspirin did not increase the severity of
gastroduodenal lesions compared to prednisone alone, or placebo. Some of the dogs in
this study did experience mild, self-limiting diarrhea when given the combination of
prednisone and low-dose aspirin. This study was performed in healthy beagle dogs, and
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the results could vary when these medications are given to clinically-ill patients. The
other concern is whether or not gastrointestinal side effects are severe enough to be
clinically relevant for the patient. The previously mentioned study did identify individual
healthy dogs from each treatment group that developed gastric and duodenal mucosa
lesions of varying severity.[47] While there was no significant difference in clinical signs
compared to the placebo group, the authors suggested that the same may not be true for
sick, geriatric, or debilitated patients.[31, 32, 48] Other studies have also shown the lack
of clinical evidence of gastrointestinal side effects in dogs treated with prednisone and
low-dose aspirin.[2]
In order to more thoroughly understand the gastrointestinal side effects of
increased doses of aspirin, and aspirin combined with prednisone, and the clinical impact
on sick or debilitated patients, additional studies are needed. First, a randomized,
prospective study evaluating these effects in healthy dogs could be performed. Physical
examination, complete blood counts, reticulocyte counts, serum iron level, total iron
binding capacity, serum ferritin, serum hepcidin, serum biochemistry, upper
gastrointestinal endoscopy with biopsies, gross fecal examination, fecal occult blood
testing, and validated psychometric quality of life tools could be performed before,
during, and after treatment. Ideally, these parameters would be evaluated in patients with
aspirin alone, aspirin and prednisone combined, and a control group. After completing a
study in healthy dogs and, if proven to be relatively safe, these methods could be used to
evaluate sick, debilitated patients as well. While it is not practical to place sick,
debilitated patients under anesthesia for elective procedures such as baseline upper

67

gastrointestinal endoscopy, modifications to the prior protocol may be utilized to include
these types of procedures once patients have been stabilized.
Another aspect of thromboprophylaxis requiring additional research is the role
and efficacy of alternative anti-platelet medications to aspirin, such as clopidogrel.
Clopidogrel has many similar appealing attributes that aspirin does, with the exception
that the proprietary product is more expensive. While proprietary clopidogrel may cost
more than aspirin, compounding either of these medications into specific and
individualized capsules makes the cost of these two medications similar. Regardless,
clopidogrel and aspirin both remain considerably less expensive than anticoagulant
treatments, and do not require frequent injections. Furthermore, the combination of
aspirin and clopidogrel has become popular in human and veterinary medicine. In fact, a
recent human study investigated the pharmacokinetics and relative bioavailability of a
fixed-dose combination capsule of clopidogrel and aspirin, and found this formulation to
be equivalent to individual formulations, with the added benefit of improved
compliance.[49, 50] In humans, using clopidogrel alone or concurrently with aspirin has
been shown to significantly reduce the incidence of thrombotic events following
myocardial infarction, ischemic stroke, vascular death, and restenosis of intracoronary
stents. [51-53] Few studies have investigated the use of clopidogrel in veterinary patients,
with only a single study showing the use of clopidogrel to be superior to aspirin. In this
particular study, cats were given either aspirin (81mg/cat every 3 days) or clopidogrel
(18.75 mg/cat once daily) for the prevention of cardiogenic arterial thromboembolism.
Cats given clopidogrel had a significantly longer survival time compared to cats receiving
aspirin.[54]
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Similar to aspirin, there have been recent human studies suggesting that 20-40%
of patients receiving clopidogrel are resistant to the drug’s anti-platelet effects, with a
subset of clopidogrel non-responders and poor responders. [55] Additional studies are
needed to determine the prevalence of clopidogrel resistance in veterinary patients, to
establish whether dual anti-platelet therapy with aspirin and clopidogrel is superior to
single drug therapy, and to determine whether the specific disease condition or species
has any influence on treatment success. In the meantime, until the incidence of
clopidogrel resistance is established in dogs, it may be wise to utilize a combination of
both aspirin and clopidogrel in patients requiring anti-platelet therapy, in order to
minimize the chances of ineffective therapy due to drug resistance.
In humans, genetic testing for sensitivity to anti-platelet medications such as
aspirin and clopidogrel is also under current investigation. Genetic variables such as
COX-1 haplotype polymorphism, P1A1/A2 polymorphism to the beta (3) subunit
(glycoprotein IIIa), polymorphism of P2Y12 receptor (H2 haplotype), and CYP2C19*2
polymorphisms have been identified in humans, and are believed to contribute to aspirin
and clopidogrel resistance.[56-59] Similar genetic polymorphisms have yet to be
investigated in veterinary medicine but, if such polymorphisms can be identified, genetic
testing prior to therapy may have the potential to become a convenient method of
recognizing potential aspirin and clopidogrel non-responders.
Ultimately, our hope with the information gained from this study is to optimize
the platelet inhibition induced by aspirin, to overcome the limitations of aspirin
resistance, and to decrease the risk of thromboembolic complications in at risk canine
patients. Additional studies are needed in order to determine if a dose of aspirin of 2
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mg/kg/day will achieve these goals, and if this dose will do so without increasing the risk
of significant complications in these patients.
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